Medine.co.uk

Spectam Scour Halt Oral Solution 50 Mg/Ml

Revised: September 2011

AN: 01097/2011


SUMMARY OF PRODUCT CHARACTERISTICS


1. NAME OF THE VETERINARY MEDICINAL PRODUCT


SpectamScour Halt oral solution 50 mg/ml


2. QUALITATIVE AND QUANTITATIVE COMPOSITION


Active ingredients: per 100ml


Spectinomycin 5.00g

(as spectinomycin dihydrochloride pentahydrate)


Other ingredients:

Benzoic acid 0.10 g

Tartzine (E102) 0.06 g


3. PHARMACEUTICAL FORM


Oral solution.

A yellow viscous aqueous solution.


4. CLINICAL PARTICULARS


4.1 Target species


Pigs (piglets)

Sheep (lambs)


4.2 Indications for use


a) For the treatment and control of enteritis caused by strains of Escherichia colisensitive to spectinomycin in piglets.


b) For the prevention of bacterial neonatal disease (e.g. watery mouth disease) in lambs which are at risk of colostrum deprivation.


4.3 Contra-indications


Known hypersensitivity to the active ingredient.

Do not use in pigs over 4 weeks of age or over 7 kg bodyweight.

Use with caution in animals suffering from renal damage


4.4 Special warnings for each target species


None


4.5 Special precautions for use, including special precautions to be taken by

the person administering the medicinal product to the animals,


i. Special precautions for use in animals


Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. If this is not possible, therapy should be based on local (regional, farm level) epidemiological information about susceptibility of the target bacteria.


ii. Special precautions to be taken by the person administering the medicinal product to animals


Do not handle in case of known hypersensivity to spectinomycin.

In case of accidental splashing on to the skin or eyes, wash the affected area with plenty of clean running water.

Wash hands thoroughly after use.


4.6 Adverse reactions (frequency and seriousness)


None known


4.7 Use during pregnancy, lactation or lay


Not applicable.


4.8 Interaction with other medicinal products and other forms of interaction


None reported


4.9 Amounts to be administered and administration route


By oral administration.

To ensure a correct dosage, body weight should be determined as accurately as possible to avoid underdosing.


Piglets: Piglets under 4.5 kg (10 lb) - 1 pump (1 ml) twice daily.

Piglets between 4.5 kg (10 lb) and 7.0 kg (15 lb) - 2 pumps (2 ml) twice daily. Treatment may be continued twice daily for 3-5 days.

If pigs do not improve within 48 hours, re-diagnosis is suggested


Lambs: 1 pump (1 ml) once only as soon as possible after birth.


Insert the doser in the bottle and push the piece of clear plastic tubing over the end of the pump spout. Press the plunger a few times to fill both the pump and plastic extension tube with medication.


The preparation should be administered well back on the tongue. Each pump of the plunger delivers 1 ml of solution containing 50 mg of spectinomycin. When not in use, remove the dosing pump from the bottle. Place the clear plastic tube in the neck of the bottle and press the plunger a few times to return any medication in the pump to the bottle. Before storing for future use, always rinse out the doser with water to prevent the pump parts from sticking.


4.10 Overdose (Symptoms, emergency procedures, antidotes)


Because the product is so poorly absorbed from the alimentary canal, it is difficult to overdose.


The symptoms of overdosage in piglets and lambs are not known. There is no known antidote to overdosage.


4.11 Withdrawal periods


Animals must not be slaughtered for human consumption during treatment.


Pigs may be slaughtered for human consumption only after 12 days from the last treatment.


Lambs may be slaughtered for human consumption only after 10 days from the last treatment.


5. PHARMACOLOGICAL PROPERTIES


Pharmacotherapeutic group: Antibacterials for systemic use, Other antibacterials


ATC Vet Code:QJ01XX04


Spectinomycin is an aminocyclitol antimicrobial and has been shown to be produced by two kinds of fungi, Streptomyces flavopersicusand Streptomyces spectabilis. It is similar to the aminoglycosides, acting by binding to ribisomal 30s subunits of the bacteria.


In-vitrotests have shown spectinomycin to be effective against a range of Gram-negative and Gram-positive bacteria, although in the field its spectrum of action is for Gram-negative bacteria. Anaerobic organisms are generally resistant.


It has been demonstrated that spectinomycin is more bacteriostatic than bactericidal. The mechanism of action appears to be by inhibition of protein synthesis.


Spectinomycin is poorly absorbed from the alimentary canal. In the blood, protein binding is low at less than 10%. It is almost totally eliminated by renal glomerular filtration with 75% or more cleared in 4 hours.


6. PHARMACEUTICAL PARTICULARS


6.1 List of excipients


Benzoic acid

Tartrazine (E102)

Hypromellose

Purified water


6.2 Major incompatibilities


None known.


6.3 Shelf-life


Shelf-life for veterinary medicine as packaged for sale: 3 years


6.4 Special precautions for storage


Do not store above 25°C


6.5 Nature and contents of container


Nature:

Container: White high density polyethylene.

Stopper: White Polypropylene.

Plunger device: Various parts consisting of polyacetal, polyethylene, polypropylene, styrene acrylonitrile, butadiene acrylonitrile rubber.

Lubricant: Polydimethylsiloxane.


Contents: 100 ml


6.6 Special precautions for the disposal of unused medicinal product or waste materials if any


Any unused product or waste material derived from such veterinary medicinal products should be disposed of n accordance with local requirements.


7. MARKETING AUTHORISATION HOLDER


CEVA Animal Health Ltd

Unit 3

Anglo Office Park

White Lion Road

Amersham

Buckinghamshire

HP7 9FB



8. MARKETING AUTHORISATION NUMBER


Vm15052/4006


9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION


Date :Renewed: 31stJuly 2002


10. DATE OF REVISION OF THE TEXT


Date :September 2011


Page 5 of 5